Table 2.

Study, outcomes, and total number of patients/patients receiving bromocriptine

Study	Total number of patients/patients receiving bromocriptine	Type of study	Outcomes
Sliwa et al. [46]	20/10	Prospective single-center, randomized	Patients treated with bromocriptine had greater improvement in LVEF at 6 months than the control group, and fewer experienced the composite endpoint compared with the control group (death, NYHA class III/IV, or LVEF < 35% at 6 months)
Yameogo et al. [47]	96/48	Prospective single-center, randomized	LVEF was similar at entry but higher in the bromocriptine group at 2 weeks and at 3, 6, and 12 months. Mortality at 6 months was higher in both groups but lower in the bromocriptine-treated women
Hilfiker-Kleiner et al. [48]	2 different regiments of bromocriptine (1 week in 27 patients vs. 8 weeks in 31 patients)	Randomized trial	The investigators postulated an association between bromocriptine and the favorable outcomes. The study was limited by the lack of a control group not receiving bromocriptine
Haghikia et al. [27]	115/64	Observational	Bromocriptine in addition to standard therapy was associated with higher rate of improvement in LVEF, but there was no significant difference in overall rates of recovery
REBIRTH (Randomized Evaluation of Bromo-criptine in Myocardial Recovery Therapy)	200	A randomized double-blind, placebo control study	Under evaluation